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Abstract
Integrating evidence from multiple domains is useful in prioritizing disease candidate genes for subsequent testing. We
ranked all known human genes (n=3819) under linkage peaks in the Irish Study of High-Density Schizophrenia Families
using three different evidence domains: 1) a meta-analysis of microarray gene expression results using the Stanley Brain
collection, 2) a schizophrenia protein-protein interaction network, and 3) a systematic literature search. Each gene was
assigned a domain-specific p-value and ranked after evaluating the evidence within each domain. For comparison to this
ranking process, a large-scale candidate gene hypothesis was also tested by including genes with Gene Ontology terms
related to neurodevelopment. Subsequently, genotypes of 3725 SNPs in 167 genes from a custom Illumina iSelect array
were used to evaluate the top ranked vs. hypothesis selected genes. Seventy-three genes were both highly ranked and
involved in neurodevelopment (category 1) while 42 and 52 genes were exclusive to neurodevelopment (category 2) or
highly ranked (category 3), respectively. The most significant associations were observed in genes PRKG1, PRKCE, and CNTN4
but no individual SNPs were significant after correction for multiple testing. Comparison of the approaches showed an
excess of significant tests using the hypothesis-driven neurodevelopment category. Random selection of similar sized genes
from two independent genome-wide association studies (GWAS) of schizophrenia showed the excess was unlikely by
chance. In a further meta-analysis of three GWAS datasets, four candidate SNPs reached nominal significance. Although
gene ranking using integrated sources of prior information did not enrich for significant results in the current experiment,
gene selection using an a priori hypothesis (neurodevelopment) was superior to random selection. As such, further
development of gene ranking strategies using more carefully selected sources of information is warranted.
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A wealth of information relevant to the genetics of complex
disorders is available via a wide variety of platforms such as gene
expression, protein-protein interactions (PPIs), biological path-
ways, and Gene Ontology (GO). It was hoped that the advent of
large scale genome-wide association studies (GWAS) would
eliminate the need to utilize this data as a means to uncover
susceptibility loci. However, psychiatric GWAS have shown that
there are likely many loci of small effect and few results are
significant after corrections for multiple testing [1,2,3]. Further-
more, the loci that do survive only account for modest proportions
of heritability. Therefore, novel methods are still needed to identify
additional causative loci. The use of multiple, existing sources of
information could increase statistical power to detect susceptibility
genes and minimize the risk of pursuing false positives in follow up
investigations. However, due to the large amount of information
plus heterogeneity among data sources, the task of combining such
information in an optimal way is complex and difficult, either
intuitively or manually.
Schizophrenia is a disorder that is particularly suitable to this
type of approach. While other complex disorders and traits such as
type 2 diabetes and height have been gathering a rapidly growing
list of replicated and validated susceptibility loci, several features of
schizophrenia will arguably make such success less likely. Although
its heritability is higher than many complex disorders such as type
2 diabetes, its prevalence is lower. This makes very large studies
with tens or hundreds of thousands of participants much more
challenging (albeit necessary in order to detect an effect). There is
also phenotypic and diagnostic heterogeneity which is arguably
less present in other complex disorders and which may reflect
genetic heterogeneity as well. Moreover, for schizophrenia, there is
increasing evidence suggesting a complex genetic architecture
comprising a mixture of rare highly-penetrant mutations such as
large deletions in gene NRXN1 [4] as well as common single
nucleotide polymorphisms (SNPs) [5]. Furthermore, well devel-
oped animal models or the availability of patient tissue are very
limited. However, there are multiple schizophrenia GWAS
available now, which can be used to evaluate hypotheses or
ranking procedures.
We have previously developed a procedure for gene ranking
based on a priori evidence and the results from a small validation
study were encouraging [6]. Here, we reported a modified ranking
procedure for complex diseases such as schizophrenia, applied it to
all genes residing in regions of linkage in the Irish Study of High
Density Schizophrenia Families (ISHDSF) sample, and performed
a larger evaluation of the method. To evaluate the utility of this
approach, we compared it with a gene selection approach based
on the well-established neurodevelopmental etiological hypothesis
of schizophrenia [7].
Materials and Methods
Ethics statement
This research was approved by the Institutional Review Boards
of Virginia Commonwealth University School of Medicine and the
Washington VA Medical Center. All subjects gave verbal assent to
participate in research, as this represented the ethical standard in
Ireland at the time these data were collected. This strategy was
specifically approved by the Health Research Board, Dublin.
Permission was received to use the data in this study, and the data
we de-identified prior to analysis.
Subjects and phenotypes
The Irish Study of High Density Schizophrenia Families
(ISHDSF) sample consists of 265 high-density schizophrenia
families with 1408 individuals available for genotyping [8]. All
participating individuals gave appropriate informed consent to the
study. The sample was divided into 4 concentric diagnostic
categories for analysis purposes, ranging from core schizophrenia
(D2, 625 affected individuals), through narrow spectrum (‘inter-
mediate phenotype’ D5, 804 affected individuals), broad (D8, 888
affected individuals) and very broad spectrum disease (D9, 1172
affected individuals). Phenotypic details of these subcategories are
given briefly in Thiselton et al. [9].
Linkage regions
We first limited the ranking to genes in regions with evidence for
linkage in the ISHDSF. These regions were obtained from an
autosomal genome-wide scan using over 4000 SNPs as part of the
Multicenter Genetic Studies of Schizophrenia (PI, Douglas F.
Levinson, MD) [10]. Regions were defined as genomic segments
with nonparametric linkage (NPL) maximum score of at least 2.0
and telomeric and centromeric boundaries of NPLs of 1.0. The
detailed genomic locations were provided in File S1. A bioinfor-
matics search of these regions yielded 3819 human protein-coding
genes.
Prior sources of information
For each of the 3819 genes, we obtained a separate p-value
pertaining to each of 3 domains: 1) gene expression, 2) protein-
protein interaction (PPI) subnetwork, and 3) high-throughput
literature search, as illustrated in Figure 1. First, the p-value for
fold-change in each gene’s expression level was obtained from the
Stanley Brain Expression Database (http://www.stanleygenomics.
org), which contains meta-analysis results using data from 12
different studies and 988 arrays. A False Discovery Rate (FDR)
procedure [11] was applied to the uncorrected p-values and used
to generate a corrected ranked p-value. Second, assuming disease
genes may be functionally connected, we identified the genes
whose proteins interact closely with proteins encoded by three
established schizophrenia susceptibility genes (DTNBP1 [12,13],
NRG1 [14,15], and AKT1 [9]) in the PPI network. A comprehen-
sive human PPI network was generated using human PPI data
retrieved from NCBI Entrez Gene (February 2007) which
summarizes interactions from multiple sources including HPRD
(http://www.hprd.org) [16], BioGrid (http://www.thebiogrid.org)
[17,18], and BIND (http://www.bind.ca) [19]. After removing
redundant and problematic interactions, 52,288 unique human
PPI pairs remained in the network. The program Pajek (http://
vlado.fmf.uni-lj.si/pub/networks/pajek/) [20] was used to deter-
mine the minimum number of steps between the proteins encoded
by DTNBP1, NRG1, and AKT1 and every other human gene in the
PPI network. Each of the 3819 genes was assigned a rank based p-
value based on the number of steps (lowest to highest). The
hypothesis is that a gene closer in the network to a probable
susceptibility gene is more likely to harbor susceptibility alleles.
Finally, high-throughput literature searching was performed using
a Perl script which automatically queried the PubMed database
(http://www.ncbi.nlm.nih.gov/pubmed/) for each of the 3819
genes along with 29 schizophrenia-related search terms that we
assembled (3819629=110,751 searches). These search terms
were divided into several categories: disease states (e.g., ‘‘schizo-
phrenia’’, ‘‘psychosis’’), neurotransmitters (e.g., glutamate, dopa-
mine), neuronal features (e.g., ‘‘dendrite’’, ‘‘axon’’), brain devel-
opment, and brain structures (e.g., ‘‘cortex’’). Genes were ranked
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‘‘hits’’, and assigned a ranked p-value.
Ranking and gene selection
For a final ranking of these genes, we summed the 2log10 of
their p-values on each of the three domains (gene expression, PPI
network, and literature search). Two subsets of the 3819 genes
were selected for tag-based SNP genotyping and association
analysis (see Figure 1). The first set was based on the commonly
accepted neurodevelopmental hypothesis of schizophrenia (‘‘hy-
pothesis-based’’) [7,21,22], where all genes with GO terms that
included ‘‘nervous system development’’ or ‘‘brain development’’
were selected. The second set was rank-based and included as
many top ranked genes as could be included on the custom array
based on the remaining unallocated SNPs. In practice, many of
the top ranked genes had already been selected by the hypothesis
procedure and were in the first set. This led to 125 of the 151 top
ranked genes being selected for genotyping with 52 being
exclusively highly ranked without being implicated in neurode-
velopment. In summary, among the 167 genes we selected for
genotyping, 73 were both highly ranked and involved in
neurodevelopment (category 1), while 42 and 52 genes were
exclusive to neurodevelopment (category 2) or highly ranked
(category 3), respectively.
SNP selection and genotyping
We then identified the genomic region of each candidate gene
based on gene annotation information in the UCSC Genome
Browser (UCSC hg17/NCBI Build 35, http://genome.ucsc.edu/).
For the genomic regions, we attempted to select all haplotype-
tagging genic SNPs within each gene using computer program
Tagger [23] (r
2=0.8, minor allele frequency (MAF)=0.1) and the
HapMap data (phase 2, http://hapmap.ncbi.nlm.nih.gov/).
Genotyping was conducted by Illumina, Inc. using a custom
iSelect array, which employs the Infinium assay. In total, genomic
DNA for 1128 individuals was submitted for genotyping. Average
genotyping completion rate across all SNPs was 99.97%. Of 1128
samples, 21 failed to yield usable genotypes. Genotypes were
examined for apparent Mendelian incompatibilities using PED-
CHECK v1.1 [24] and removed for entire families where
appropriate. After excluding SNPs failing quality control, 3725
SNPs were available for analysis.
Association analyses
Association analysis for categorical diagnoses of schizophrenia
was performed using PDTPHASE (UNPHASED v.2.404), an
implementation of the pedigree disequilibrium test (PDT) with
extensions to deal with uncertain haplotypes and missing data
[25,26]. The PDT is an extension of the transmission disequilib-
rium test (TDT) to examine general pedigree structures and is
similarly a test of association in the presence of linkage.
GWAS datasets
The International Schizophrenia Consortium (ISC) samples
were collected from eight study sites in Europe and the US [1].
The samples were genotyped using Affymetrix Genome-Wide
Human SNP 5.0 and 6.0 arrays. This data was initially analyzed
by ISC [1] and was used here for evaluation. A total of 3322
patients with schizophrenia, 3587 normal controls of European
ancestry, and a total of 739,995 SNPs were included in our
analysis. To account for potential population sub-structure
associated with collection sites, the Cochran-Mantel-Haenszel test
was used for a single marker association test [1].
We used two GWAS datasets from the Molecular Genetics of
Schizophrenia (MGS): The Genetic Association Information
Network (GAIN) dataset for schizophrenia and nonGAIN. The
GAIN dataset was genotyped using Affymetrix Genome-Wide
Human SNP 6.0 array. Our access to this dataset was approved by
the GAIN Data Access Committee (DAC request #4532-2)
through the NCBI dbGaP. For optimal comparison with the Irish
samples (ISHDSF) genotyped in this study, we used only the
GAIN samples of European ancestry. We performed quality
control (QC) as follows. For individuals, those with a high missing
genotype rate (.5%), extreme heterozygosity rate (63 s.d. from
the mean value of the distribution), or problematic gender
assignment were excluded. PLINK [27] was used to compute
the identify-by-state (IBS) matrix to pinpoint duplicate or cryptic
relationships between individuals. We retained the sample with the
highest call rate for each pair of samples with an identity-by-
descent (IBD) being greater than 0.185. Principle component
analysis (PCA) was performed using the smartpca program in
EIGENSTRAT [28] to detect population structure and to allow
removal of outlier individuals. Eight significant PCs with the Tracy
Widom test p-value,0.05 were used as covariates for logistic
regression (additive model). For genotyped SNPs, those with a
missing genotype rate .5%, MAF ,0.05, or departing from
Hardy-Weinberg equilibrium (p,1610
26) were removed. The
final analytic dataset included 1158 schizophrenia cases and 1377
controls and a total of 654,271 SNPs. The genomic inflation factor
(l), which was defined as the ratio of the median of the empirically
observed distribution of the test statistic to the expected median
and an indication of the extent of excess false positive rate [29],
was 1.04. This value indicates little (if any) inflation.
Figure 1. Flowchart of data process, algorithm for gene
ranking and selection, custom-based genotyping and associ-
ation analysis.
doi:10.1371/journal.pone.0067776.g001
Schizophrenia Gene Selection and Association
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e67776The MGS - nonGAIN dataset was genotyped in the same
laboratory as the MGS -GAIN, but in different phases. Access to
this dataset was approved by dbGaP (DAC request #4533-3).
Similar QC and PCA processes were peformed as described for
GAIN. These processes retained 1068 cases and 1268 controls and
623,059 SNPs for subsequent analyses. Fifteen significant PCs with
the Tracy-Widom test p value,0.05 were used as covariates for
logistic regression (additive model) using PLINK. The genomic
inflation factor (l) was 1.04.
CATIE (Clinical Antipsychotic Trials of Intervention Effective-
ness) is a multi-phase randomized controlled trial of antipsychotic
medications involving 1460 persons with schizophrenia. CATIE
GWAS included 492,900 SNPs genotyped in a total of 738 cases
and 733 group-matched controls using the Affymetrix 500K two-
chip genotyping platform plus a custom 164K fill-in chip [30].
Access to this dataset was approved by the National Institute of
Mental Health (NIMH) Schizophrenia Genetics Initiative.
Imputation and meta-analysis
The three GWAS datasets, ISC, GAIN, and nonGAIN, were
genotyped on the same Affymetrix platform. To make the data
from these GWAS datasets comparable with our custom-design
SNPs, we conducted imputation analysis using the HapMap
genotyping data for CEU population (release 24) as reference
panel. We predicted the genotyping data for a total of 66 SNPs
involved in 22 genes using the tool impute2 [31]. Frequentist
association test was then conducted for SNP association using the
tool snptest [32] by the option ‘‘-frequentist 1’’, and a missing data
likelihood score test for the imputed genotypes by the option ‘‘-
method score’’.
We conducted meta-analysis of candidate SNPs using the
imputed data. We performed inverse-variance weighted meta-
analysis based on the fixed-effects model using the tool meta
(http://www.stats.ox.ac.uk/,jsliu/meta.html). This method com-
bines study-specific beta values under the fixed-effects model using
the inverse of the corresponding standard errors as weights.
Between-study heterogeneity was tested based on I
2 and Q
statistics. SNPs having possible evidence of heterogeneity
(pheterogeneity,0.05) were removed.
Gene set simulations
In order to determine how often the observed enrichment in p-
values would occur, 100,000 simulations were performed where
the same number of genes was randomly chosen from the CATIE
and GAIN GWAS results. Then, p-values less than 0.05 and 0.005
for genotyped SNPs that mapped to the randomly chosen genes
were counted. Due to the great variation in gene size, SNP density
per gene, and difference in arrays used in each GWAS, the
number of SNPs in each iteration of the simulations could vary.
Therefore, we examined whether the observed number of SNPs
for the real set of ranked genes was similar to randomly selected
sets. The empirical significance for SNP count, minimum p-value,
and p-values below a given threshold were calculated both using
all simulations and restricted to those simulations where the SNP
count was not significantly different from observed. The empirical
significance was calculated using the number of simulations
greater than or equal to the observed plus one divided by the
total number of simulations as per North et al. [33].
Results
Figure 1 summarizes the data process, algorithm for gene
ranking and selection, custom-based genotyping and association
analysis. We analyzed 3725 SNPs covering 167 prioritized genes
whose genotypes were examined in 1107 individuals from the 265
high-density schizophrenia families using a custom Illumina iSelect
array. This gene list included 115 genes selected by neurodevel-
opmental hypothesis and 125 genes selected by gene ranking
algorithm – 73 were common between these two selection
categories (see Materials and Methods). The minimum p-value
among these 3725 tested SNPs was 0.000536 in gene PRKG1 (SNP
rs1904687). This gene was chosen as part of the neurodevelop-
mental hypothesis since it ranked only 954
th of the 3819 genes.
Table 1 shows the genes with at least one SNP whose p-value was
,0.01 and their test category and rank. Results for all SNPs tested
are available in File S2. Although there were three SNPs with p-
values less than 0.001 in PRKG1, 247 SNPs were tested in this
large gene. Therefore, none of the SNPs were significant after
gene- or experiment-wide correction for multiple testing (Bonfer-
roni correction, which is a stringent correction). A False Discovery
Rate (FDR) analysis of all tests also supported this conclusion, with
a minimum FDR based q-value of 0.719.
A number of genes, including PRKG1, CNTN4, and PRKCE,
contained clusters of nominally significant SNPs (p,0.01): 17
SNPs in PRKG1, 9 SNPs in CNTN4, and 5 SNPs in PRKCE (see
File S2). Of these three genes, two were from the neurodevelop-
mental set exclusively and one (PRKCE) was from the combined
hypothesis and highly rank categories. Gene rank was not
correlated with the minimum p-value observed in the tested
genes. There was an enrichment of significant p-values in the
neurodevelopment group; however, surprisingly, the ranked genes
Table 1. Summary of genes with at least one significant
(p,0.01) SNP.
Gene Category Rank # SNPs Min p-value
PRKG1 2 954 247 0.000536
PRKCE 1 35 229 0.001321
CNTN4 2 645 381 0.001474
EMX1 2 549 2 0.001949
INSR 1 109 51 0.001975
XPO1 3 88 2 0.001978
VAV3 3 98 76 0.002273
UTRN 3 99 56 0.002886
SH3GL2 2 538 74 0.003219
NPAS2 3 96 55 0.003419
IL19 3 149 8 0.003559
EGFR 3 8 67 0.004041
NRP1 2 291 56 0.004202
HLA-DRA 3 144 11 0.004317
MAL 2 361 4 0.004592
CNTN6 2 862 146 0.005419
VAV2 1 132 66 0.006312
PPP2R2B 3 151 47 0.007685
IKBKB 1 65 4 0.008221
MGMT 3 78 52 0.008672
NOTCH1 2 439 15 0.009058
GRIA1 3 101 67 0.009981
Category 1: genes are both highly ranked and involved in neurodevelopment.
Category 2: genes are exclusive to neurodevelopment. Category 3: genes are
exclusively highly ranked (see details in Materials and Methods).
doi:10.1371/journal.pone.0067776.t001
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number of genes, SNPs, and p-values by category is provided in
Table 2.
Comparison with published schizophrenia GWAS results
We compared the current results to two published schizophre-
nia GWAS datasets, the Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE) GWAS dataset [30] and the GAIN
dataset from Molecular Genetics of Schizophrenia (MGS) [2] (see
Materials and Methods). Simulated gene selection was used to
determine how often the observed enrichment would occur if the
whole genome was assessed. Lists of genes were randomly selected
100,000 times using the same numbers of genes selected in the
three selection categories (73, 42, and 52 for categories 1, 2, and 3,
respectively). Unfiltered simulation showed that the number of
SNPs per gene in the current study was significantly higher than
for randomly selected genes from either the CATIE or GAIN
study. Therefore, the tests for significant enrichment of p-values
below 0.05 and 0.005 are biased in the unfiltered simulations. To
reduce the bias, random gene sets were ranked based on the total
number of SNPs. Different rank filtering thresholds were tested
until there was no significant difference in total number of SNPs
between the observed and simulated sets. The rank filter
thresholds necessary to achieve non-significance were quite
different for the CATIE and GAIN studies with the top 500 and
10,000 being used respectively. The filtered simulations showed
the ‘neurodevelopment only’ category to be significantly
(p=0.012) and marginally (p=0.058) enriched for p-values less
than 0.005 in the CATIE and MGS-GAIN samples, respectively.
Further details of the simulation results are in Table 3.
Meta-analysis
In our SNP list, there were 66 SNPs with p,0.01. These SNPs
belonged to 22 genes. We examined them in a meta-analysis using
three schizophrenia GWAS datasets (ISC, GAIN and nonGAIN).
Using the inverse-variance weighted meta-analysis method, we
identified 3 SNPs in 3 genes that showed nominal significance
(p,0.05) (Table 4). None of them had significant heterogeneity by
heterogeneity test. These SNPs are rs2176348 in PRKCE (p-
value=0.044), rs552551 in MGMT (p-value=0.044), and
rs2616591 in CNTN4 (p-value=0.048). Another SNP, rs2043534
in NPAS2, had marginal significance (p-value=0.062). However,
none of these SNPs passed Bonferroni multiple testing correction.
We further examined the association signals of these SNPs using
the data from the Psychiatric Genomics Consortium (PGC), the
largest and most comprehensive cohort dataset for schizophrenia
association studies so far [34]. Among the 66 SNPs, 24 were not
available in the public release of the PGC dataset (https://pgc.
unc.edu/Sharing.php); thus, they could not be imputed due to the
lack of access to PGC’s raw genotyping data. For the 42 SNPs that
had p-values in the PGC dataset, we found that three were
nominally significant (p,0.05), including one SNP (rs2616591) in
Table 4. Of note, for the four SNPs that were significant or
marginally significant in the meta-analysis of our SNPs (Table 4),
two were available in the PGC dataset including SNP rs2616591
that had a small p value (1.68610
23).
Discussion
In this study, we attempted to develop gene ranking strategies
based on either evidence from multiple domains (meta-analysis of
gene expression, proteins closely interacting with well-studied
schizophrenia susceptibility genes, and a systematic literature
search) or the neurodevelopmental hypothesis and then applied
them to the genes under linkage peaks in the Irish Study of High-
Density Schizophrenia Families. For the top ranked genes, we
tested their associations with schizophrenia using a custom
Illumina iSelect array. The association signals were further
evaluated using three GWAS datasets (ISC, GAIN, and non-
GAIN). Although none of the SNPs were robustly associated,
clusters of significant SNPs were found in several large genes
including PRKG1, CNTN4, and PRKCE. These genes were tested
not due to rank but as part of the neurodevelopmental hypothesis.
This category showed enrichment for significant association
signals, and simulations showed this enrichment is unlikely to be
due to chance.
There is additional evidence that makes the top results of
interest in addition to the reason they were originally tested.
CNTN4 (contactin 4) is a neural cell adhesion molecule whose
gene has been reported to be associated with autism and
developmental delay in multiple studies [35,36,37]. Interestingly,
another member of the contactin family, CNTNAP2, has been
found to be associated with both schizophrenia and autism [38].
PRKG1 and PRKCE are known as protein kinase cGMP-
dependent, type I and protein kinase C epsilon, respectively.
Although they are both protein kinases, they are functionally
distinct and activated via different mechanisms. PRKG1 is
dependent on cyclic GMP for activation while PRKCE is
activated by calcium and the second messenger diacylglycerol.
PRKG1 has previously shown its association with schizophrenia
with the 21
st most significant SNP in the CATIE GWAS [30].
PRKG1 also interacts with RGS2 and GABRR1, which have
Table 2. Summary of genes and number of SNPs per test category.
Category # genes # SNPs Highly rankedNeuro-development
Mean p-
value SNPs with p,0.05 SNPs with p,0.005
Obs. Exp. Obs. Exp.
1 73 1271 Yes Yes 0.521 42 63.6 4 6.4
2 42 1525 No Yes 0.480 103 76.3 17 7.6
3 52 929 Yes No 0.488 63 46.5 2 4.6
1+2 115 2796 - Yes 0.498 145 139.8 21 14.0
1+3 125 2200 Yes - 0.507 105 110.0 6 11.0
All 167 3725 208 186.3 23 18.6
Category 1: genes are both highly ranked and involved in neurodevelopment. Category 2: genes are exclusive to neurodevelopment. Category 3: genes are exclusively
highly ranked (see details in Materials and Methods).
doi:10.1371/journal.pone.0067776.t002
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schizoaffective disorder [40], respectively. Finally, PRKG1 can
attenuate beta-catenin expression [41], which is a known
downstream target of antipsychotics [42]. PRKCE interacts with
several proteins encoded by genes of potential relevance to
psychiatric disorders, including the glutamate decarboxylases
(GAD1, GAD2), NMDA receptors (GRIN2D, GRIN1), and a
metabotropic glutamate receptor (GRM5). PRKCE is also
activated by the stimulation of nicotinic receptors [43]. Although
these genes were not highly ranked, prior evidence makes them all
plausible candidates for schizophrenia. Therefore, each could be
chosen using expanded sources of prior information and a refined
ranking procedure.
There are several limitations to the current work that could be
potentially improved in future application. First, the primary
filtering of genes in the genome was done using linkage results
from the ISHDSF. Due to the large number of risk variants in
schizophrenia, there are likely to be many true associations outside
of these regions. The second limitation is the small number of
genes and minimum step approach used for the PPI network sets.
We used three well-studied genes (DTNBP1, NRG1, and AKT1)i n
this work. More informative genes including microRNA genes
(e.g., miR-137 [34,44] and TCF4 [3,34]) were recently reported to
be associated with schizophrenia and could improve this
approach. Larger networks or results from more comprehensive
network analyses are probably superior; nevertheless, this work
proves the concept using more closely related genes in the PPI
Table 3. Comparison of ISHDSF rank and hypothesis based gene selection results to random gene selection in schizophrenia
CATIE and GAIN GWAS datasets.
Category
a Simulation Empirical p-value
Method
b Observed in ISHDSF CATIE GWAS GAIN GWAS
100,000
c Top 500
d 100,000
c Top 10,000
d Top 500
d
All SNP count 3741 0.00097 0.194 0.066 0.659 0.998
min p-value 0.000582 0.618 0.896 0.787 0.879 0.964
# SNPs with p,0.05 208 0.0019 0.208 0.158 0.767 1
# SNPs with p,0.005 23 0.0258 0.234 0.241 0.614 0.924
1 SNP count 1271 0.079 0.655 0.389 0.806 0.892
min p 0.001975 0.729 0.872 0.859 0.920 0.956
# SNPs with p,0.05 42 0.586 0.914 0.887 0.976 0.986
# SNPs with p,0.005 4 0.556 0.836 0.780 0.895 0.934
2 SNP count 1525 0.0022 0.104 0.017 0.121 0.267
min p 0.000582 0.214 0.349 0.319 0.398 0.445
# SNPs with p,0.05 103 0.00042 0.032 0.017 0.102 0.232
# SNPs with p,0.005 17 0.00294 0.012 0.018 0.058 0.142
3 SNP count 929 0.088 0.591 0.358 0.707 0.822
min p 0.003559 0.797 0.926 0.883 0.932 0.972
# SNPs with p,0.05 63 0.049 0.427 0.264 0.558 0.719
# SNPs with p,0.005 2 0.701 0.896 0.837 0.914 0.954
aCategory 1: genes are both highly ranked and involved in neurodevelopment. Category 2: genes are exclusive to neurodevelopment. Category 3: genes are exclusively
highly ranked (see details in text).
bWe performed simulations by four methods: 1) based on the count of SNPs, 2) based on the minimum p-value, 3) based on the number of SNPs with p,0.05, and 4)
based on the number of SNPs with p,0.005.
c100,000 simulations (see text).
dTo reduce bias, simulations were filtered with top 500 or 10,000 SNPs being used (see Materials and Methods).
doi:10.1371/journal.pone.0067776.t003
Table 4. Four SNPs from the meta-analysis of 66 SNPs using GAIN, nonGAIN, and ISC GWAS datasets.
Gene SNP ID Chr. Position (bp) Allele Meta-analysis
p-value Beta s.e. pheterogeneity I
2 pGAIN pnonGAIN pISC IHDS min p
PRKCE rs2176348 2 45798033 A/G 0.044 20.064 0.032 0.838 0 0.470 0.599 0.057 0.004
MGMT rs552551 10 131271915 C/T 0.044 0.073 0.036 0.29 19.15 0.996 0.797 0.011 0.009
CNTN4 rs2616591 3 2614861 C/T 0.048 0.088 0.044 0.481 0 0.347 0.061 NA 0.004
NPAS2 rs2043534 2 100847317 C/T 0.062 0.064 0.035 0.635 0 0.258 0.808 0.081 0.003
Chr.: chromosome. GAIN, nonGAIN and ISC are three GWAS datasets for meta-analysis. ISHDSF min p was the smallest p-value in the gene from the IHDS dataset (this
study). NA: this SNP was not analyzed in ISC due to missing genotyping data in samples.
doi:10.1371/journal.pone.0067776.t004
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to be useful, it might include underpowered studies, negative
findings, or studies with methodological flaws or reported false
positive results. This is a common problem in literature mining,
which could be improved by careful manual check or advanced
literature mining technologies like natural language processing
(NLP). In our study, gene ranking was performed by the combined
evidence from three domains (gene expression meta-analysis, PPI
subnetwork, and literature mining). This strategy might help
reduce the noisy data from literature mining. Finally, besides the
well-supported neurodevelopmental hypothesis, we may test other
hypotheses or the candidate genes for samples with refined
characterization of phenotypic spectrum. For example, Green-
wood et al. [45] recently tested a set of schizophrenia candidate
genes in schizophrenia-related endophenotypes, suggesting both
converging and independent genetic pathways mediating schizo-
phrenia risk and pathogenesis.
There are several ways to improve or expand the gene selection
and prioritization approaches. First, we may develop a more
comprehensive data integration approach. This includes the
integration of data from multiple domains such as gene expression,
copy number variation (CNV), methylation, microRNA, associa-
tion results, etc. This has been demonstrated in our weight matrix
approach for evidence scores [46], as well as other approaches like
convergent analysis [47,48,49] and microRNA regulatory network
analysis [50]. Of note, TCF4 gene, along with three other genes
reported in the PGC meta-analysis (CACNA1C, CSMD1 and
C10orf26), has predicted miR-137 target sites [34]. This makes the
microRNA-mediated regulatory analysis promising in schizophre-
nia. In terms of the algorithm, we may apply Bayesian approach,
or a comprehensive network and pathway approach, to those
multi-domain datasets, since the underlying biological information
and regulation is expected to be much related in a complex
disease. For example, we recently demonstrated our network
approach in schizophrenia [51]. Such approach can be expanded
in future by including transcriptional (transcription factors,
methylation) and post-transcriptional (microRNA) regulation.
Second, with the rapid advances in high throughput technologies,
such as Exome chip or next-generation sequencing, we may
prioritize the candidate genes that show association signals
detected by both common and rare variants and that are involved
in disease-related altered genomic regions such as CNVs or
structural variants (SVs). This approach benefits from cross-
platform and cross-study validation.
In summary, we did not find compelling association evidence
for any individual gene selected either by evidence-based gene-
ranking or by the rank based on its relevance to the neurodevel-
opmental hypothesis. However, the neurodevelopmental set of
genes showed enrichment for significant associations when
examined en masse. Finally, several tested genes have additional
independent evidence not used in the ranking that make them
attractive candidates for further investigation.
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